Insulin Glargine News and Research

RSS
Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

What are the mediators linking cardiometabolic risk factors and severe COVID-19?

What are the mediators linking cardiometabolic risk factors and severe COVID-19?

Two popular drugs to treat type 2 diabetes performed best in large clinical trial

Two popular drugs to treat type 2 diabetes performed best in large clinical trial

Large clinical trial compares four drugs commonly used to treat type 2 diabetes

Large clinical trial compares four drugs commonly used to treat type 2 diabetes

First interchangeable biosimilar insulin product approved by FDA for treatment of diabetes

First interchangeable biosimilar insulin product approved by FDA for treatment of diabetes

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

No lasting improvement in insulin secretion with diabetic medication

No lasting improvement in insulin secretion with diabetic medication

Mylan and Biocon launch new insulin glargine biosimilar in the UK

Mylan and Biocon launch new insulin glargine biosimilar in the UK

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

Researchers compare different types of insulin in treating patients with type 1 or 2 diabetes

Researchers compare different types of insulin in treating patients with type 1 or 2 diabetes

Type 2 diabetes can be reversed with intensive medical treatment, study shows

Type 2 diabetes can be reversed with intensive medical treatment, study shows

New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Drug combination improves glucose control in Type 2 diabetes patients

Drug combination improves glucose control in Type 2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes